Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07753681 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System

Study acronym: PEN Plus
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study First Submitted
8,786 trials monitored
See 412 trials at risk
5,087 trials monitored
See 222 trials at risk
1,995 trials monitored
See 111 trials at risk
and 3 more diseases
Cognizant of the prevalence of complicated non communicable diseases (NCD) and the attendant capacity problems faced by the health workers in primary care settings, we propose to adapt and pilot the Package of Essential Non-communicable Diseases (PEN) Plus intervention using the Interactive Systems Framework (ISF) and then implement and monitor the impact. The ISF framework proposes and organizes several implementation strategies to achieve Evidence Based Implementation (EBI) adaptation. We will apply these strategies at 2 first level hospitals (Peri-Urban and Rural) to ensure local adaptation and work towards scaling up of the WHO-PEN Plus in the rest of Zambia. This process will be inclusive, involving a Stakeholder Consultation Group that shall include the Zambian Non-Communicable diseases and injuries (NCDI) Poverty Commission and shall report bi-annually to a Project Advisory Board (PAB) chaired by the Permanent Secretary of the Ministry of Health.
Trial Details
NCT Number NCT07753681
Lead Sponsor Centre for Infectious Disease Research in Zambia
Collaborators: The Leona M. and Harry B. Helmsley Charitable Trust
Conditions
(from sponsor)
Cardiac Diseases, Sickle Cell Disease, Hypertension, Diabetes Mellitus, Heart Failure, Congenital Heart Disease, Rheumatic Heart Disease, Epilepsy +3 more
Related terms Anemia, Sickle Cell, Diabetes Mellitus, Epilepsy, Heart Defects, Congenital, Heart Diseases, Heart Failure, Hypertension, Kidney Diseases, Neoplasms, Rheumatic Heart Disease
Enrollment 2,084 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov